Insulin, intermediate and long-acting

No definition available.

Endpoint definition

FinnGen phenotype data
diagram bullet diagram downward connector

Filter registries KELA purch., KELA reimb.

Medicine purchases: ATC A10AE01|A10AE0[4-6]|A10AE30
Medicine purchases: ATC: other data required >3 instances required

Check pre-conditions None

Include endpoints None

Check conditions None

Apply sex-specific rule None

diagram downward connector INSULIN_INTER_AND_LONG

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

Key figures

All Female Male
Number of individuals 14120 6059 8061
Unadjusted prevalence (%) 5.43 4.12 7.13
Mean age at first event (years) 51.65 49.30 53.41

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.09 7.68 [6.62, 8.91] <1e-100 1735
15 years 0.05 7.81 [6.74, 9.05] <1e-100 1729
5 years 0.01 8.89 [7.75, 10.19] <1e-100 852
1 year 0.00 4.60 [3.60, 5.88] 4.9e-34 93

Correlations

Index endpoint: INSULIN_INTER_AND_LONG – Insulin, intermediate and long-acting
GWS hits:

Survival analyses between endpoints

Plot

before Insulin, intermediate and long-acting
after Insulin, intermediate and long-acting

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Insulin, intermediate and long-acting